ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc
essa pharma - Masofaniten和Enzalutamide的組合在MCRPC患者中繼續良好耐受,並可持久降低PSA水平
ESSA Pharma - Combination of Masofaniten Plus Enzalutamide Continues to Be Well Tolerated With Durable Reductions in Psa in Patients With Mcrpc
essa pharma - Masofaniten和Enzalutamide的組合在MCRPC患者中繼續良好耐受,並可持久降低PSA水平
譯文內容由第三人軟體翻譯。